NR1H4 and glomerulosclerosis: Lack of FXR accelerated DKD disease progression23 while FXR agonist (GW4064 and INT‐747) treatment improved insulin resistance and renal lipid accumulation, as well as ameliorated proteinuria, glomerulosclerosis and tubulointerstitial fibrosis in diabetic mice models by downregulating renal expression of SREBPs.24, 25